AJOVY contains fremanezumab for migraine prevention. Its US label separates adult schedules from the pediatric episodic-migraine indication, which has both age and body-weight limits.
The approved uses and formulations described here follow US prescribing information. They may differ in other countries.
| Medicine detail | Details |
|---|---|
| Active ingredient(s) | fremanezumab-vfrm |
| Medicine class | CGRP antagonist monoclonal antibody |
| Forms and strengths | Subcutaneous injection: 225 mg/1.5 mL single-dose prefilled autoinjector or syringe |
Adult and pediatric indications differ
AJOVY is labeled for preventing migraine in adults and episodic migraine in children aged 6 to 17 who weigh at least 45 kg. The pediatric indication does not cover every child with migraine. Age, weight and episodic disease must all be retained when describing eligibility.
Source: [1]
One presentation, different adult schedules
The cited presentation is 225 mg in 1.5 mL in a single-dose autoinjector or prefilled syringe. Adults have labeled monthly or quarterly options; the quarterly amount involves three consecutive injections. The pediatric schedule is different. A clinician selects the plan, and device training is needed before home administration.
Source: [1]
The updated constipation warning
The current label includes constipation with serious complications. Contact the treating team about severe constipation, particularly with significant abdominal symptoms. Injection-site reactions are also reported. A new symptom after an injection should not automatically be dismissed because earlier doses were tolerated.
Source: [1]
Delayed allergy and vascular precautions
Hypersensitivity reactions have been reported from hours to a month after administration. Serious reactions need immediate medical attention. New or worsening hypertension and Raynaud's phenomenon are additional warnings. Report blood-pressure changes and painful, cold or discolored digits promptly so continued treatment can be assessed.
Source: [1]
Record the plan before the next injection
Keep the device, prescribed schedule and last administration date clear. Do not move between monthly and quarterly plans or exchange another migraine antibody using a milligram calculation. Product-specific storage and preparation instructions remain necessary; the availability of a label does not establish stock or personal access.
You can explore selected factual differences in the AIMOVIG and AJOVY comparison, alongside each medicine’s own prescribing information.
Source: [1]
Questions and answers
Is AJOVY labeled for every child aged 6 or older?
No. The pediatric indication is episodic migraine at ages 6 to 17 with body weight at least 45 kg.
Is the adult quarterly dose a separate stronger device?
The cited label describes the quarterly amount as three consecutive injections of the 225 mg presentation.
Can an AJOVY allergic reaction be delayed?
Yes. The label describes reactions from hours to a month after administration; severe symptoms require urgent care.
Related reading
Sources
Sources checked 27 October 2026. This information does not replace advice from your healthcare professional. For complete warnings and instructions, read the product information and consult the prescribing team.
Reviewed by: Mattias Hagman, PhD
About the reviewer:
Dr Mattias Hagman (PhD, University of Sydney) has an academic background and experience working with healthcare-related content and regulated industries. He has lecturing experience at international universities, including Stockholm University and the University of Malta.
Last reviewed: October 2026